MarketPulse

chronic lymphocytic leukemia

3 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly's Jaypirca Notches Fourth Phase 3 Win, Strengthening Blood Cancer Portfolio

Eli Lilly reports fourth positive Phase 3 trial for Jaypirca in chronic lymphocytic leukemia, positioning drug for label expansion ahead of competitive launches.
JNJABBVLLYPhase 3 trialprogression-free survival
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Posts $87.2M Loss While Advancing Bexobrutideg Clinical Pipeline

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.
SNYGILDNRIXclinical trialsimmunology
BenzingaBenzinga··Vandana Singh

FDA Clears Oral Combination Therapy for Untreated Chronic Lymphocytic Leukemia

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.
ABBVRHHBYAZNFDA approvalPhase 3 trial